Grifols, S.A. (GRFS) Income Statement

The reported figures indicate that Grifols' revenue has plateaued, with quarterly growth oscillating between -3.2% and +4.0% over the past year, reflecting a mature plasma market and limited pricing power. The slight uptick in gross margin in 2026Q2, despite flat revenue, implies that the company may be benefiting from favorable product mix or earlier cost-saving initiatives, though the sustainability of this trend is uncertain given the lack of volume growth. Investors should monitor whether the company can translate its operational stability into meaningful top-line expansion, especially as the divestment of Shanghai RAAS proceeds may provide cash but not growth.

The data shows that gross margin is structurally constrained, with the 40.3% peak in 2025Q3 followed by a decline to 37.6% in 2026Q2, suggesting that cost per liter pressures are re-emerging. This volatility indicates that Grifols' margin expansion is limited by its ability to control collection costs, which are influenced by U.S. labor market conditions and donor incentives. The company's gross margin is comparable to CSL's 35.7%, but Grifols' lower operating margin (17.6% vs. 19.9%) suggests less operational efficiency, possibly due to higher SG&A or R&D intensity.

While gross profit grew modestly, operating income in 2026Q2 was $329M, down from $348.9M in the prior year quarter, despite similar revenue levels. This suggests that the company is experiencing cost inflation in SG&A and R&D, which are not being fully absorbed by revenue growth. The increase in R&D spending, particularly in 2025Q4 ($135.5M), may reflect investments in new product development, but it is pressuring near-term profitability. Investors should watch whether management can rein in overhead costs to restore operating leverage as revenue growth remains stagnant.

The cost structure reveals that SG&A is a significant drag, with 2026Q2 SG&A at $289M, up from $282.8M in 2025Q2, despite flat revenue. R&D spending has also been volatile, with a notable increase in 2025Q4, which may reflect clinical trial costs for pipeline products. These rising costs are compressing operating margins, which fell from 20.5% in 2025Q3 to 17.6% in 2026Q2. Management's ability to control these expenses while maintaining growth investments will be critical for margin recovery.